![Judith Ng-Cashin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Judith Ng-Cashin
Nessuna posizione attualmente
Storia della carriera di Judith Ng-Cashin
Precedenti posizioni note di Judith Ng-Cashin
Società | Posizione | Inizio | Fine |
---|---|---|---|
EAGLE PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 02/11/2020 | 27/12/2021 |
AOBiome Therapeutics, Inc.
![]() AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Direttore Tecnico/Scientifico/R&S | - | - |
Formazione di Judith Ng-Cashin
Duke University | Undergraduate Degree |
Rush Medical College | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 5 |
Posizioni
Chief Tech/Sci/R&D Officer | 2 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Settori
Health Technology | 3 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
EAGLE PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 1 |
---|---|
AOBiome Therapeutics, Inc.
![]() AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Judith Ng-Cashin
- Esperienza